Suven Pharmaceuticals Acquires 56% Stake in NJ Bio for $64.4 Million
Suven Pharmaceuticals Limited has announced the acquisition of a 56% equity stake in NJ Bio, Inc., a Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in antibody-drug conjugates (ADCs) and related technologies. The acquisition involves a mix of secondary share purchases and a primary equity infusion, amounting to $64.4 million. As part of the transaction, […]